The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Viral Kinetics and Antibody Responses in Patients with COVID-19
Open accessAbstract
Background: A pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been spreading over the world. However, the viral dynamics, host serologic responses, and their associations with clinical manifestations, have not been well described in prospective cohort. Methods: We conducted a prospective cohort and enrolled 67 COVID-19 patients admitting between Jan 26 and Feb 5, 2020. Clinical specimens including nasopharyngeal swab, sputum, blood, urine and stool were tested periodically according to standardized case report form with final follow-up on February 27. The routes and duration of viral shedding, antibody response, and their associations with disease severity and clinical manifestations were systematically evaluated. Coronaviral particles in clinical specimens were observed by transmission electron microscopy (TEM). Results: The median duration of SARS-CoV-2 RNA shedding were 12 (3-38), 19 (5-37), and 18 (7-26) days in nasopharyngeal swabs, sputum and stools, respectively. Only 13 urines (5.6%) and 12 plasmas (5.7%) were viral positive. Prolonged viral shedding was observed in severe patients than that of non-severe patients. Cough but not fever, aligned with viral shedding in clinical respiratory specimens, meanwhile the positive stool-RNA appeared to align with the proportion who concurrently had cough and sputum production, but not diarrhea. Typical coronaviral particles could be found directly in sputum by TEM. The anti-nucleocapsid-protein IgM started on day 7 and positive rate peaked on day 28, while that of IgG was on day 10 and day 49 after illness onset. IgM and IgG appear earlier, and their titers are significantly higher in severe patients than non-severe patients ( p <0.05). The weak responders for IgG had a significantly higher viral clearance rate than that of strong responders ( p = 0.011). Conclusions: Nasopharyngeal, sputum and stools rather than blood and urine, were the major shedding routes for SARS-CoV-2, and meanwhile sputum had a prolonged viral shedding. Symptom cough seems to be aligned with viral shedding in clinical respiratory and fecal specimens. Stronger antibody response was associated with delayed viral clearance and disease severity. Summary boxes: What is already known on this topic: As a newly appearing infectious disease, early efforts have focused on virus identification, describing the epidemiologic characteristics, clinical course, prognostics for critically illed cases and mortality. Among COVID-19 cases reported in mainland China (72 314 cases, updated through February 11, 2020), 81% are mild, 14% are severe, and 5% are critical. The estimated overall case fatality rate (CFR) is 2.3%. Some case series reported had shown that SARS-CoV-2 could shed in upper/lower respiratory specimens, stools, blood and urines of patients. However, important knowledge gaps remain, particularly regarding full kinetics of viral shedding and host serologic responses in association with clinical manifestations and host factors. What this study adds: The incubation period has no change after spreading out of Wuhan, and has no sex or age differences, however, children had prolonged incubation period. Due to early recognition and intervention, COVID-19 illness of Chongqing cohort is milder than that of Wuhan patients reported. This prospective cohort study on SARS-CoV-2 infection shows clearly that the viral and serological kinetics were related in duration of infection, disease severity, and clinical manifestations of COVID-19. Our data demonstrate that nasopharyngeal, sputum and stools are major shedding routes for SARS-CoV-2, and stronger NP antibody response is associated with delayed viral clearance and disease severity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
Self-citationClinical characteristics of coronavirus disease 2019 in China
Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002032 · Cited by 30,246
Self-citationA novel coronavirus from patients with pneumonia in China, 2019
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244
Self-citationChen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y., Wei, Y., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30211-7 · Cited by 21,415
Self-citationWang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., et al. (2020) · JAMA · doi:10.1001/jama.2020.1585 · Cited by 20,148
Self-citationLa certeza de lo impredecible: Cultura Educación y Sociedad en tiempos de COVID19
Martínez González, M. (2020) · DSPACE System - Metalibrary (University of the Coast) · Cited by 18,463
Wu, Z., & McGoogan, J. M. (2020) · JAMA · doi:10.1001/jama.2020.2648 · Cited by 17,016
Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia
Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., Ren, R., Leung, K. S. M., Lau, E. H. Y., Wong, J. Y., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001316 · Cited by 16,575
Self-citationCoronaviridae Study Group of the International Committee on Taxonomy of Viruses, Gorbalenya, A. E., Baker, S. C., Baric, R. S., de Groot, R. J., Drosten, C., Gulyaeva, A. A., Haagmans, B. L., Lauber, C., Leontovich, A. M., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0695-z · Cited by 8,403
Virological assessment of hospitalized patients with COVID-2019
Wölfel, R., Corman, V. M., Guggemos, W., Seilmaier, M., Zange, S., Müller, M. A., Niemeyer, D., Jones, T. C., Vollmar, P., Rothe, C., et al. (2020) · Nature · doi:10.1038/s41586-020-2196-x · Cited by 6,661
Cited by
Immunology of COVID-19: Current State of the Science
Vabret, N., Britton, G. J., Gruber, C., Hegde, S., Kim, J., Kuksin, M., Levantovsky, R., Malle, L., Moreira, A., Park, M. D., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.05.002 · Cited by 1,623
Cevik, M., Tate, M., Lloyd, O., Maraolo, A. E., Schafers, J., & Ho, A. (2021) · The Lancet Microbe · doi:10.1016/s2666-5247(20)30172-5 · Cited by 1,350
Huang, A. T., Garcia-Carreras, B., Hitchings, M. D. T., Yang, B., Katzelnick, L. C., Rattigan, S. M., Borgert, B. A., Moreno, C. A., Solomon, B. D., Trimmer-Smith, L., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18450-4 · Cited by 1,026
Hansen, C. H., Michlmayr, D., Gubbels, S. M., Mølbak, K., & Ethelberg, S. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00575-4 · Cited by 586
Antibody tests for identification of current and past infection with SARS-CoV-2
Deeks, J. J., Dinnes, J., Takwoingi, Y., Davenport, C., Spijker, R., Taylor-Phillips, S., Adriano, A., Beese, S., Dretzke, J., Ferrante di Ruffano, L., et al. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013652 · Cited by 655
SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates
Poland, G. A., Ovsyannikova, I. G., & Kennedy, R. B. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32137-1 · Cited by 572
Acute SARS-CoV-2 Infection Impairs Dendritic Cell and T Cell Responses
Zhou, R., To, K. K.-W., Wong, Y.-C., Liu, L., Zhou, B., Li, X., Huang, H., Mo, Y., Luk, T.-Y., Lau, T. T.-K., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.07.026 · Cited by 531
The potential danger of suboptimal antibody responses in COVID-19
Iwasaki, A., & Yang, Y. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0321-6 · Cited by 509
Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past
Shah, V. K., Firmal, P., Alam, A., Ganguly, D., & Chattopadhyay, S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01949 · Cited by 475
Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients
Sun, B., Feng, Y., Mo, X., Zheng, P., Wang, Q., Li, P., Peng, P., Liu, X., Chen, Z., Huang, H., et al. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1762515 · Cited by 473
Evaluation of SARS-CoV-2 serology assays reveals a range of test performance
Whitman, J. D., Hiatt, J., Mowery, C. T., Shy, B. R., Yu, R., Yamamoto, T. N., Rathore, U., Goldgof, G. M., Whitty, C., Woo, J. M., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0659-0 · Cited by 454
Garcia-Basteiro, A. L., Moncunill, G., Tortajada, M., Vidal, M., Guinovart, C., Jiménez, A., Santano, R., Sanz, S., Méndez, S., Llupià, A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17318-x · Cited by 408
Antibody response to SARS-CoV-2 infection in humans: A systematic review
Post, N., Eddy, D., Huntley, C., van Schalkwyk, M. C. I., Shrotri, M., Leeman, D., Rigby, S., Williams, S. V., Bermingham, W. H., Kellam, P., et al. (2020) · PLOS ONE · doi:10.1371/journal.pone.0244126 · Cited by 374
Serology testing in the COVID-19 pandemic response
Peeling, R. W., Wedderburn, C. J., Garcia, P. J., Boeras, D., Fongwen, N., Nkengasong, J., Sall, A., Tanuri, A., & Heymann, D. L. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30517-x · Cited by 360
T cell response to SARS-CoV-2 infection in humans: A systematic review
Shrotri, M., van Schalkwyk, M. C. I., Post, N., Eddy, D., Huntley, C., Leeman, D., Rigby, S., Williams, S. V., Bermingham, W. H., Kellam, P., et al. (2021) · PLOS ONE · doi:10.1371/journal.pone.0245532 · Cited by 350
In Vitro Diagnostic Assays for COVID-19: Recent Advances and Emerging Trends
Vashist, S. K. (2020) · Diagnostics · doi:10.3390/diagnostics10040202 · Cited by 336
Schultheiß, C., Paschold, L., Simnica, D., Mohme, M., Willscher, E., von Wenserski, L., Scholz, R., Wieters, I., Dahlke, C., Tolosa, E., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.06.024 · Cited by 333
Padoan, A., Cosma, C., Sciacovelli, L., Faggian, D., & Plebani, M. (2020) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2020-0443 · Cited by 293
Antibody Tests in Detecting SARS-CoV-2 Infection: A Meta-Analysis
Kontou, P. I., Braliou, G. G., Dimou, N. L., Nikolopoulos, G., & Bagos, P. G. (2020) · Diagnostics · doi:10.3390/diagnostics10050319 · Cited by 288
Immune life history, vaccination, and the dynamics of SARS-CoV-2 over the next 5 years
Saad-Roy, C. M., Wagner, C. E., Baker, R. E., Morris, S. E., Farrar, J., Graham, A. L., Levin, S. A., Mina, M. J., Metcalf, C. J. E., & Grenfell, B. T. (2020) · Science · doi:10.1126/science.abd7343 · Cited by 285
Antibody testing for COVID-19: A report from the National COVID Scientific Advisory Panel
Adams, E. R., Ainsworth, M., Anand, R., Andersson, M. I., Auckland, K., Baillie, J. K., Barnes, E., Beer, S., Bell, J. I., Berry, T., et al. (2020) · Wellcome Open Research · doi:10.12688/wellcomeopenres.15927.1 · Cited by 278
Prospects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
What policy makers need to know about COVID-19 protective immunity
Altmann, D. M., Douek, D. C., & Boyton, R. J. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30985-5 · Cited by 223
“8, 18 In this group, around 90% develop IgG antibodies within the first 2 weeks of symptomatic infection and this appearance coincides with disappearance of virus, 18 supporting a causal relationship between these events.”
On the whereabouts of SARS-CoV-2 in the human body: A systematic review
Trypsteen, W., Van Cleemput, J., Snippenberg, W. V., Gerlo, S., & Vandekerckhove, L. (2020) · PLOS Pathogens · doi:10.1371/journal.ppat.1009037 · Cited by 199
Microstructure, pathophysiology, and potential therapeutics of COVID‐19: A comprehensive review
Singh, S. P., Pritam, M., Pandey, B., & Yadav, T. P. (2021) · Journal of Medical Virology · doi:10.1002/jmv.26254 · Cited by 166
“used to assess infectious cases in a mere 10minutes, after 10 to 30 days and 20 days of antibody production, respectively.(109) Moreover, such tests require only a small volume of blood (10‐20 μL).”
SARS-CoV-2 neutralizing antibody responses are more robust in patients with severe disease
Wang, P., Liu, L., Nair, M. S., Yin, M. T., Luo, Y., Wang, Q., Yuan, T., Mori, K., Solis, A. G., Yamashita, M., et al. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1823890 · Cited by 122
Recovery from COVID-19 in a B-cell-depleted multiple sclerosis patient
Wurm, H., Attfield, K., Iversen, A. K., Gold, R., Fugger, L., & Haghikia, A. (2020) · Multiple Sclerosis Journal · doi:10.1177/1352458520943791 · Cited by 36
Metadata
- Authors
- Tan, W., Lu, Y., Zhang, J., Wang, J., Dan, Y., Tan, Z., He, X., Qian, C., Sun, Q., Hu, Q., Liu, H., Ye, S., Xiang, X., Zhou, Y., Zhang, W., Guo, Y., Wang, X.-H., He, W., Wan, X., Sun, F., Wei, Q., Chen, C., Pan, G., Xia, J., Mao, Q., Chen, Y., & Deng, G.
- Venue
- medRxiv
- Publisher
- openRxiv
- Published
- 2020-03-26
- OpenAlex
- W3015060295
- Cited by
- 301
- References
- 21
- Type
- posted content
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.